skip to content
Home

 

Department of Biochemistry

 

COVID-19 projects

Illustration of the SARS-CoV-2 virus.
Read more at: Modulation of host cell RNA-binding proteins through the infectious cycle of SARS-CoV-2
Schematic representation of the OOPS method.

Modulation of host cell RNA-binding proteins through the infectious cycle of SARS-CoV-2

Kathryn Lilley and her long-term collaborator, Anne Willis (MRC Toxicology Unit), have formed an international consortium of researchers, along with collaborators from the pharmaceutical industry, to interrogate host protein-viral RNA interactions.

Read more at: Analysing the human-coronavirus RNA interactome
Illustration of the SARS-CoV-2 virus.

Analysing the human-coronavirus RNA interactome

Omer Ziv and his colleagues are employing cutting-edge tools to dissect the crosstalk between human and coronavirus RNA.

Read more at: COVID-19 diagnostics for Africa
Dr Samir Hamaia in the laboratory.

COVID-19 diagnostics for Africa

The Jackson Group are part of a wider consortium that includes researchers from Cambridge, continental Europe and Africa that together will develop and test in clinical settings assays for the detection of SARS-CoV-2 virus RNA and exposure to COVID-19 in patients.

Read more at: Development of multiplex serological assays for evaluation of SARS-CoV-2 immunity
Illustration of the SARS-CoV-2 virus.

Development of multiplex serological assays for evaluation of SARS-CoV-2 immunity

The Hyvönen Group and their collaborators are producing and utilising SARS-CoV-2 proteins to employ FBAR sensor technology for COVID-19 serological tests.

Read more at: Targeting conserved RNA elements in SARS-CoV-2 for therapy
Members of the Luisi Group in the laboratory during lockdown.

Targeting conserved RNA elements in SARS-CoV-2 for therapy

The Luisi Group and a large team of international collaborators are working to develop drugs against the SARS-CoV-2 virus, focusing particularly on the highly-structured, highly-conserved s2m RNA element.

Read more at: Affinity reagents for functional neutralisation of nCoV-19
Illustration of the SARS-CoV-2 virus.

Affinity reagents for functional neutralisation of nCoV-19

The Hollfelder Group are using directed evolution to select for proteins with potential viral binding properties for use in diagnostic assays or as antiviral drugs.

Read more at: Structural and computational biology of COVID-19
SARS-CoV-2-human protein-protein interactions.

Structural and computational biology of COVID-19

The Blundell Group are using multifaceted approaches to identify potential drug targets and inhibitors against SARS-CoV-2.

Contact us

Department of Biochemistry
Hopkins Building
Downing Site
Tennis Court Road
Cambridge
CB2 1QW

Contact: communications@bioc.cam.ac.uk

About this site

Connect with us

Study at Cambridge

About the University

Research at Cambridge